Integrated Molecular, Cellular, and Imaging Characterization of NLST detected lung cancer
Integrated Molecular, Cellular, and Imaging Characterization of NLST detected lung cancer
批准号:
10415430
负责人:
DENISE R. ABERLE
金额:
$15.6万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-22 至 2022-08-31
关键词:
AddressAggressive Clinical CourseAggressive behaviorAllelesBehaviorBiologicalCellsClinicalClinical ManagementDNADevelopmentEffectivenessFundingGenesGenomicsGoalsHealth PolicyImageImmuneImmunofluorescence ImmunologicIndividualIndolentLungLung NeoplasmsMalignant NeoplasmsMalignant neoplasm of lungMedicareModelingMolecularMutationOutcomePatientsPhenotypePreventive serviceResearchResectedRoleSamplingSeaSmokerSomatic MutationSpecimenThird-Party PayerThoracic RadiographyTissue MicroarrayTissue StainsTissuesTumor BiologyX-Ray Computed Tomographybasebiobankcancer diagnosiscellular imagingclinical decision-makingclinical heterogeneitycomputed tomography screeningexome sequencinggenomic datahigh risklow dose computed tomographylung cancer screeningmortalitynew therapeutic targetnovelpersonalized managementprecision medicinescreeningtumortumor-immune system interactions
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
The landmark NLST demonstrated a 20% mortality reduction in lung cancer in individuals who underwent low
dose computed tomography (LDCT) screening relative to plain chest radiography. The results of the NLST
have resulted in a sea change in US health policy, such that third party payers and Medicare now provide
LDCT screening as a preventive service benefit in eligible, high risk smokers. Understanding the factors
underlying tumor indolence or aggression that result in heterogeneous clinical outcomes, may facilitate clinical
decision making in the context of lung cancer screening and thereby greatly increase its effectiveness. We
hypothesize that the mutational landscape of screen-detected lung cancers is an important contributor to their
indolence or aggressiveness. To address this hypothesis we will take advantage of the comprehensively
annotated NLST biorepository. Whole exome sequencing (WES) of the previously collected NLST samples will
be performed to determine the genomic features that distinguish between screen-detected indolent and
aggressive lung tumors that result in heterogeneous clinical outcomes. Samples from 110 patients with
aggressive cancers and 494 with indolent cancers along with matching reference tissues will be assessed. By
utilizing WES, we will be able to identify the impact of genes not previously associated with lung cancer as well
as novel alleles of genes with known roles in lung cancer. This will be the first comprehensive genomic
characterization of aggressive and indolent lung cancers diagnosed in the course of a lung cancer screening
trial. The detailed genomic and imaging-based characterization of screen-detected tumors will ultimately
impact clinical management of those cancers. Through separate funding, we will also integrate the genomic
data obtained through this research with the tumor immune microenvironment (as characterized by multiplex
immunofluorescence analysis of the same specimens) and CT imaging features to build integrated,
multiparametric models of tumor biology that can be used to predict the biological behavior of lung cancers in
the screening setting.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Drug Development for Metastasis Prevention.
预防转移的药物开发。
DOI:
10.1615/critrevoncog.v20.i5-6.150
发表时间:
2015
期刊:
Critical reviews in oncogenesis
影响因子:
--
作者:
[Fontebasso Y, Dubinett SM]
通讯作者:
Dubinett SM
DOI:
10.1186/s13059-017-1191-5
发表时间:
2017-03-24
期刊:
Genome biology
影响因子:
12.3
作者:
[Kang S, Li Q, Chen Q, Zhou Y, Park S, Lee G, Grimes B, Krysan K, Yu M, Wang W, Alber F, Sun F, Dubinett SM, Li W, Zhou XJ]
通讯作者:
Zhou XJ
DOI:
10.1158/2159-8290.cd-20-1087
发表时间:
2020-10
期刊:
Cancer discovery
影响因子:
28.2
作者:
[Krysan K, Tran LM, Dubinett SM]
通讯作者:
Dubinett SM
DOI:
10.1016/j.ctarc.2021.100486
发表时间:
2021
期刊:
Cancer treatment and research communications
影响因子:
--
作者:
[Burks EJ, Zhang J, Sullivan TB, Shi X, Sands JM, Regis SM, McKee BJ, McKee AB, Zhang S, Liu H, Liu G, Spira A, Beane J, Lenburg ME, Rieger-Christ KM]
通讯作者:
Rieger-Christ KM
Understanding the mechanisms of immune-evasion by lung cancer in the context of chronic inflammation in emphysema.
了解肺气肿慢性炎症背景下肺癌免疫逃避的机制。
DOI:
10.21037/jtd.2019.01.22
发表时间:
2019
期刊:
Journal of thoracic disease
影响因子:
2.5
作者:
[Salehi-Rad,Ramin, Dubinett,StevenM]
通讯作者:
Dubinett,StevenM
Individually-tailored clinical decision support for management of indeterminate pulmonary nodules
-
批准号:10307996
-
项目类别:
-
资助金额:$45.55万
-
财政年份:2018
-
负责人:DENISE R. ABERLE
-
依托单位:
EFIRM-Liquid Biopsy (eLB): Ultrasensitive ctDNA and miRNA Detection for Early Assessment of Lung Cancer
-
批准号:9982813
-
项目类别:
-
资助金额:$66.96万
-
财政年份:2018
-
负责人:DENISE R. ABERLE
-
依托单位:
EFIRM Liquid Biopsy Research Laboratory: Early Lung Cancer Assessment
-
批准号:10763321
-
项目类别:
-
资助金额:$93.21万
-
财政年份:2018
-
负责人:DENISE R. ABERLE
-
依托单位:
EFIRM-Liquid Biopsy (eLB): Ultrasensitive ctDNA and miRNA Detection for Early Assessment of Lung Cancer
-
批准号:10225427
-
项目类别:
-
资助金额:$67.03万
-
财政年份:2018
-
负责人:DENISE R. ABERLE
-
依托单位:
EFIRM-Liquid Biopsy (eLB): Ultrasensitive ctDNA and miRNA Detection for Early Assessment of Lung Cancer
-
批准号:10456340
-
项目类别:
-
资助金额:$64.72万
-
财政年份:2018
-
负责人:DENISE R. ABERLE
-
依托单位:
Individually-tailored clinical decision support for management of indeterminate pulmonary nodules
-
批准号:10055957
-
项目类别:
-
资助金额:$46.48万
-
财政年份:2018
-
负责人:DENISE R. ABERLE
-
依托单位:
Individually-tailored clinical decision support for management of indeterminate pulmonary nodules
-
批准号:10539247
-
项目类别:
-
资助金额:$44.76万
-
财政年份:2018
-
负责人:DENISE R. ABERLE
-
依托单位:
Molecular and Imaging Biomarkers for Early Lung Cancer Detection in the Setting of Indeterminate Pulmonary Nodules
-
批准号:10018815
-
项目类别:
-
资助金额:$62.78万
-
财政年份:2016
-
负责人:DENISE R. ABERLE
-
依托单位:
Molecular and Imaging Biomarkers for Early Lung Cancer Detection in the Setting of Indeterminate Pulmonary Nodules
-
批准号:10231155
-
项目类别:
-
资助金额:$18.11万
-
财政年份:2016
-
负责人:DENISE R. ABERLE
-
依托单位:
The Boston University-UCLA Lung Cancer Biomarker Development Lab
-
批准号:9277841
-
项目类别:
-
资助金额:$56.57万
-
财政年份:2016
-
负责人:DENISE R. ABERLE
-
依托单位:
Molecular and Imaging Biomarkers for Early Lung Cancer Detection in the Setting of Indeterminate Pulmonary Nodules
-
批准号:9357555
-
项目类别:
-
资助金额:$62.75万
-
财政年份:2016
-
负责人:DENISE R. ABERLE
-
依托单位:
The Boston University-UCLA Lung Cancer Biomarker Development Lab
-
批准号:10463887
-
项目类别:
-
资助金额:$21.66万
-
财政年份:2016
-
负责人:DENISE R. ABERLE
-
依托单位:
Molecular and Imaging Biomarkers for Early Lung Cancer Detection in the Setting of Indeterminate Pulmonary Nodules
-
批准号:9194508
-
项目类别:
-
资助金额:$67.65万
-
财政年份:2016
-
负责人:DENISE R. ABERLE
-
依托单位:
The Boston University-UCLA Lung Cancer Biomarker Development Lab
-
批准号:10011778
-
项目类别:
-
资助金额:$41.78万
-
财政年份:2016
-
负责人:DENISE R. ABERLE
-
依托单位:
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer
-
批准号:10253429
-
项目类别:
-
资助金额:$62.49万
-
财政年份:2015
-
负责人:DENISE R. ABERLE
-
依托单位:
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer
-
批准号:9145156
-
项目类别:
-
资助金额:$223.99万
-
财政年份:2015
-
负责人:DENISE R. ABERLE
-
依托单位:
MULTIMEDIA ARCHITECTURE FOR THORACIC DISEASES
-
批准号:6430471
-
项目类别:
-
资助金额:$15.28万
-
财政年份:2001
-
负责人:DENISE R. ABERLE
-
依托单位:
PACS FOR THORACIC IMAGING
-
批准号:6366899
-
项目类别:
-
资助金额:$31.9万
-
财政年份:1998
-
负责人:DENISE R. ABERLE
-
依托单位:
PACS FOR THORACIC IMAGING
-
批准号:6102594
-
项目类别:
-
资助金额:$31.9万
-
财政年份:1998
-
负责人:DENISE R. ABERLE
-
依托单位:
PACS FOR THORACIC IMAGING
-
批准号:6237114
-
项目类别:
-
资助金额:$32.29万
-
财政年份:1997
-
负责人:DENISE R. ABERLE
-
依托单位: